Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Subscribe To Our Newsletter & Stay Updated
